Last reviewed · How we verify
TNX-103
TNX-103 is a cardiac myosin inhibitor that reduces the force of heart muscle contraction to improve cardiac function in heart failure patients.
TNX-103 is a cardiac myosin inhibitor that reduces the force of heart muscle contraction to improve cardiac function in heart failure patients. Used for Heart failure with preserved ejection fraction (HFpEF).
At a glance
| Generic name | TNX-103 |
|---|---|
| Sponsor | Tenax Therapeutics, Inc. |
| Drug class | Cardiac myosin inhibitor |
| Target | Cardiac myosin |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
TNX-103 selectively inhibits cardiac myosin, the motor protein responsible for heart muscle contraction. By reducing contractility in a controlled manner, it decreases cardiac workload and oxygen demand while improving diastolic function. This mechanism is intended to provide symptomatic relief and improve exercise tolerance in patients with heart failure.
Approved indications
- Heart failure with preserved ejection fraction (HFpEF)
Common side effects
- Reduced ejection fraction
- Fatigue
- Dizziness
Key clinical trials
- Long-Term Open-Label Extension Study of Oral Levosimendan (PHASE3)
- LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2 (PHASE3)
- LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |